Emergent nets another manufacturing deal, this time for Ridgeback's Ebola treatment
While Covid-19 and monkeypox currently dominate headlines and social health priorities, government officials aren’t forgetting about Ebola and its potential for serious outbreaks.
Emergent BioSolution inked an agreement last week with Ridgeback Biotherapeutics in a collaboration to expand the availability of Ebola treatment Ebanga. Under the deal, Emergent will be responsible for the manufacturing, sale and distribution of Ebanga in the US and Canada. Ridgeback Bio for its part will serve as the global partner for the drug and ensure it remains available to patients in endemic countries free of charge through its compassionate use program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.